Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4

Christina A. Von Roemeling, Derek C Radisky, Laura A. Marlow, Simon J. Cooper, Stefan K. Grebe, Panagiotis Z Anastasiadis, Han W Tun, John A III Copland

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.

Original languageEnglish (US)
Pages (from-to)4796-4810
Number of pages15
JournalCancer Research
Volume74
Issue number17
DOIs
StatePublished - Sep 1 2014

Fingerprint

alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Glutamate Receptors
Renal Cell Carcinoma
Cell Movement
Neoplasms
Kidney Neoplasms
Cell Survival
Neoplasm Metastasis
Acids
neuronal pentraxin
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. / Von Roemeling, Christina A.; Radisky, Derek C; Marlow, Laura A.; Cooper, Simon J.; Grebe, Stefan K.; Anastasiadis, Panagiotis Z; Tun, Han W; Copland, John A III.

In: Cancer Research, Vol. 74, No. 17, 01.09.2014, p. 4796-4810.

Research output: Contribution to journalArticle

@article{d9c370d6f01f4da6801eb4b791516b09,
title = "Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4",
abstract = "Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.",
author = "{Von Roemeling}, {Christina A.} and Radisky, {Derek C} and Marlow, {Laura A.} and Cooper, {Simon J.} and Grebe, {Stefan K.} and Anastasiadis, {Panagiotis Z} and Tun, {Han W} and Copland, {John A III}",
year = "2014",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-14-0210",
language = "English (US)",
volume = "74",
pages = "4796--4810",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4

AU - Von Roemeling, Christina A.

AU - Radisky, Derek C

AU - Marlow, Laura A.

AU - Cooper, Simon J.

AU - Grebe, Stefan K.

AU - Anastasiadis, Panagiotis Z

AU - Tun, Han W

AU - Copland, John A III

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.

AB - Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84907059429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907059429&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0210

DO - 10.1158/0008-5472.CAN-14-0210

M3 - Article

C2 - 24962026

AN - SCOPUS:84907059429

VL - 74

SP - 4796

EP - 4810

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -